Cyclodextrins (CDs) attracted increasing interest over the past few years, leading to the emergence of promising anti-tumor nanomedicines. Tackling their advantageous chemical structure, ease of modification, natural origin, biocompatibility, low immunogenicity, and commercial availability, researchers investigated CD-based therapeutical formulations against many types of cancer including gastrintestinal, breast, reproductive, kidney, brain, bone and other cancers. Various CDs, including the native ones, the derivatives produced industrially and those prepred for targeted delivery of certain antitumor agent are discussed.
Paduraru, D.N.; Niculescu, A.-G.; Bolocan, A.; Andronic, O.; Grumezescu, A.M.; Bîrla, R. An Updated Overview of Cyclodextrin-Based Drug Delivery Systems for Cancer Therapy. Pharmaceutics 2022, 14, 1748. https://doi.org/10.3390/pharmaceutics14081748